NEWTOWN, Pa. -- CollaGenex Pharmaceuticals, Inc. (Nasdaq: CGPI) today announced restructuring plans following the approval by the FDA of a generic form of Periostat(R) for sale by IVAX Pharmaceuticals Inc. and CorePharma, LLC. Unless an injunction is ordered, CollaGe...

NEWTOWN, Pa. -- CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) today announced that Colin W. Stewart, president and chief executive officer, will present at the Jefferies Life Sciences Conference. The presentation is scheduled for 12:30 p.m. EDT on Thursday, June...

NEWTOWN, Pa. -- CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) today announced that it will hold a conference call on Tuesday, August 7, 2007, at 11:00 a.m. Eastern Time to discuss the Company's second quarter and first half 2007 financial results. A press releas...

NEWTOWN, Pa. -- CollaGenex Pharmaceuticals, Inc. (NASDAQ: CGPI CGPI - Capital Goods Price Index (New Zealand)CGPI - Corporate Goods Price Index (Japan)) today announced that it has submitted its response to the U.S. Patent and Trademark Office's non-final rejection o...

NEWTOWN, Pa. -- CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) today announced that the U.S. Patent and Trademark Office (USPTO USPTO - United States Patent and Trademark Office) has listed the status of its patent application No. 10/117,709, covering Oracea(TM) (the...

Business Editors/Health/Medical Writers NEWTOWN, Pa.--(BUSINESS WIRE)--April 22, 2003 Periostat Significantly Reduced Lesion Counts in Patients with Moderate Facial Acne bromide acne  an acneiform eruption without comedones, one of the most constant symptoms of b...

Business Editors/Health/Medical Writers NEWTOWN, Pa.--(BUSINESS WIRE)--July 14, 2003 Publication includes a comprehensive description of the rationale for treating Acne and Rosacea rosacea /ro·sa·cea/ (ro-za´she-ah) a chronic disease of the skin of the nose...

Study Demonstrated Clear Dose-Response Relationship with Excellent Safety Profile; Incyclinide, 20 mg, A Safe and Effective Dose; Dose Optimization Study Continues Company to Host Conference Call and Webcast Today at 11:00 a.m. Eastern Time NEWTOWN, Pa. -- ...

Business Editors/Health/Medical Writers NEWTOWN, Pa.--(BUSINESS WIRE)--March 20, 2003 Combined Products Address $250MM Potential Topical Acne & Rosacea rosacea /ro·sa·cea/ (ro-za´she-ah) a chronic disease of the skin of the nose, forehead, and cheeks, m...

Total Revenues of $16.4 Million Including $13.1 Million in Oracea Sales NEWTOWN, Pa. -- CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) today reported financial results for the second quarter and six months ended June 30, 2007. Net revenues were $16.4 millio...

NEWTOWN, Pa. -- CollaGenex Pharmaceuticals, Inc. (Nasdaq:CGPI) today announced that the National Institutes of Health ("NIH") has awarded a grant of approximately $962,000 for additional research into the potent anti-inflammatory effects of incyclinide (form...

CollaGenex Pharmaceuticals Announces a Report in the Journal of the American Academy of Dermatology ...

NEWTOWN, Pa. -- CollaGenex Pharmaceuticals, Inc. (Nasdaq:CGPI) today announced the results of a double-blinded, placebo-controlled Phase 2 clinical study designed to evaluate the safety and efficacy of COL-3 for the treatment of rosacea. Col-3 is a second-generation I...

Chris Pandel is chef at Osteria Via Stato in Chicago, where he is working under executive chef/partners Rick Tramonto and David DiGregorio. Most recently, Pandel worked for Tramonto at Tru, also in Chicago ... ...

Business Editors/Health & Medical Writers ...

NEWTOWN, Pa. -- CollaGenex Pharmaceuticals, Inc. (Nasdaq:CGPI) today announced that Colin Stewart, president and chief executive officer, will present at Roth Capital Partners New York Conference. The presentation is scheduled for 4:00 p.m. Eastern Time on Monday Sept...

NEWTOWN, Pa. -- Reissuing release to correct earnings and conference call date. ...

NEWTOWN, Pa. -- CollaGenex Pharmaceuticals, Inc. (Nasdaq:CGPI) today announced that the U.S. Patent and Trademark Office (USPTO) has published on its website that U.S. Patent Application, serial no. 10/117,709, has been allowed. This patent covers the use of sub-antim...

NEWTOWN, Pa. -- CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) today reported financial results for the quarter ended September 30, 2005. Total revenues for the third quarter of 2005 were $4.5 million compared to $11.1 million in the third quarter of 2004. During the ...